Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma

Sorafenib, the only approved drug for hepatocellular carcinoma, acts as a remarkable inhibitor of Raf serine‐threonine kinases. However, Sorafenib is expensive, and clinical experience shows that it is not an effective treatment for many patients. Previous study has demonstrated that phosphorylated...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yuelong, Chen, Jiang, Yu, Qingsong, Ji, Tong, Zhang, Bin, Xu, Junjie, Dai, Yi, Xie, Yangyang, Lin, Hui, Liang, Xiao, Cai, Xiujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727337/
https://www.ncbi.nlm.nih.gov/pubmed/29030911
http://dx.doi.org/10.1002/cam4.1228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727337/
https://www.ncbi.nlm.nih.gov/pubmed/29030911
http://dx.doi.org/10.1002/cam4.1228

Ejemplares similares